<DOC>
	<DOCNO>NCT00789750</DOCNO>
	<brief_summary>The current study investigates Welchol add-on therapy pioglitazone improve glycemic control subject Type 2 Diabetes Mellitus adequately control pioglitazone monotherapy pioglitazone combination either metformin sulfonylurea . The study evaluate Welchol add-on pioglitazone therapy Type 2 Diabetes Mellitus safe , well tolerate , efficacious .</brief_summary>
	<brief_title>Welchol Add-on Pioglitazone Therapy Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Colesevelam Hydrochloride</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<criteria>Diagnosis Type 2 Diabetes Mellitus . Inadequate glycemic control stable dose ( least 2 month prior screen ) pioglitazone 30 45 mg/day , without one two oral antidiabetic medication ( metformin sulfonylurea . DPPIV inhibitor ) A1C &gt; = 7.5 % = &lt; 9.5 % screening . Fasting plasma glucose = &lt; 240 mg/dL randomization ( Week0/Day 1 ) . Male female &gt; = 18 year age . Women childbearing potential ( WOCBP ) must use adequate method contraception detail perprotocol . Fasting Cpeptide level &gt; 0.5 ng/mL screening . Clinically stable regard medical condition type 2 diabetes . Concomitant medication stable dos least 30 day prior enrollment , anticipated need adjustment study period . History Type 1 diabetes and/or history ketoacidosis . History bowel obstruction History hypertriglyceridemiainduced pancreatitis Fasting serum triglyceride concentration &gt; 500 mg/dL History dysphagia , swallow disorder , gastroparesis , gastrointestinal motility disorder , major gastrointestinal surgery History insulin use &gt; = 2 week duration previous 3 month total &gt; 2 month insulin therapy time prior screen Two fasting selfmonitored blood glucose ( SMBG ) level &gt; 240 mg/dL placebo leadin period Body mass index &gt; 40 kg/m2 screen Weight loss &gt; 3 % 3 month prior screen Treatment bile acid sequestrants , include Welchol within 3 month prior screen LDL level &lt; 60 mg/dL Female subject pregnant breastfeeding SBP &gt; = 180 mmHg and/or DBP &gt; = 110 mmHg History unstable angina , myocardial infarction , cerebrovascular accident , transient ischemic attack , revascularization within 6 month prior screen History malignancy , except subject diseasefree &gt; 10 year whose malignancy basal squamous cell skin carcinoma . Women history cervical dysplasia ( CIN2 high ) exclude unless 2 consecutive normal cervical smear subsequently record prior enrollment Known ( evidence ) infection human immunodeficiency virus ( HIV ) History alcohol drug abuse within 1 year prior screen History untreated major psychiatric disorder could inhibit ability comply protocol Any condition , lab abnormality concomitant therapy , opinion investigator , might pose risk subject make participation subject 's best interest Known suspect allergy , hypersensitivity intolerance excipients investigational study medication Participation interventional medical , surgical , pharmaceutical study within 30 day prior screen visit A direct familial relationship sponsor , investigator , site personnel affiliate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>